Trials / Completed
CompletedNCT00804908
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 346 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | temozolomide | temozolomide capsule administered orally once daily for 5 days every 28 days |
| DRUG | ABT-888 | ABT-888 capsule administered orally twice daily for 7 days every 28 days |
| OTHER | Placebo | Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2008-12-09
- Last updated
- 2018-06-06
- Results posted
- 2017-03-03
Source: ClinicalTrials.gov record NCT00804908. Inclusion in this directory is not an endorsement.